Top Tweets for #DetermaIO
It was a great #ASCO23! Thanks to everyone who stopped by the booth to learn more about #DetermaIO.
Contact our attendees in case you missed it or have follow up questions here: https://t.co/jTPtf5840b
#OCX $OCX #Immunotherapy #WhereTomorrowLives
Today kicks off #CancerImmunotherapyMonth hosted by @CancerResearch, who helps to raise awareness of the lifesaving potential of immunotherapy for all types of cancer. Learn how #DetermaIO can help identify patients who may benefit from immunotherapy: https://t.co/L3EE1UL3DK
Oncocyte is proud to be presenting five posters at #AACR2023 highlighting exciting research using #DetermaIO and #DetermaCNI! Read more here:
https://t.co/HpxjLwXouw
#OCX $OCX #Immunotherapy #WhereTomorrowLives
.@OncocyteCorp : STUDY RESULTS PUBLISHED IN CLINICAL CANCER RESEARCH JOURNAL $OCX #DetermaIO #Biotechnology #stockstowatch #StocksInFocus
https://t.co/LOyF54F8Lp
We are excited to announce a new publication in #ClinicalCancerResearch that highlights the results of a study that applied #DetermaIO to the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer.
Read it here: https://t.co/8usW9cbWlk
#CRC #OCX $OCX
Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer - More like this https://t.co/Ch0OzV8Nyh | @OncocyteCorp @CCR_AACR #DetermaIO #ClinicalTrial #ClinicalData #coloncancer #metastasis #Cancer #Biotech https://t.co/cafF4FgeoJ
#DetermaIO works by measuring and algorithmically weighing the signals of an activated TIME against signals of resistance from immunosuppressive or immune desert conditions within the TIME.
Learn more at https://t.co/ZWxcaGUUc2
#wheretomorrowlives
We need a better way to identify patients who are more likely to receive benefit from immunotherapies. #DetermaIO provides a comprehensive picture of the TIME to help identify these patients. What Sets DetermaIO™ Apart?
Learn more: https://t.co/QJRzD0qMVX
#wheretomorrowlives
Excited to share the publication of a new paper in #CancerImmunology, #Immunotherapy that highlights the performance of #DetermaIO’s algorithm and IO score in a second independent cohort of metastatic urothelial carcinoma patients. https://t.co/5DP4gZgT0G #wheretomorrowlives $OCX
The latest publication in Clinical #LungCancer on #DetermaIO continues to show its ability to impact patient decision making when it comes to ICI treatment decisions. Exciting work! #cancerawareness #wheretomorrowlives #teamoncocyte $OCX https://t.co/zuoUkEAhjC
When the TIME is right for Immunotherapy! #DetermaIO has been studied in 6 different tumor types & shown to be predictive of ICI benefit. Novel 27-gene assessment of the tumor-immune microenvironment to identify patients who may benefit from immunotherapy. https://t.co/rJdOtBqxMw
We need a betterway to identify the patients who are more likely to receive benefit from immunotherapies. #DetermaIO provides a comprehensive picture of the TIME to identify patients that may benefit from immunotherapy. What Sets DetermaIO™ Apart?
To be partnered with SWOG, in a prospectively designed biomarker study in a large, randomized clinical trial, marks a major milestone for #DetermaIO.”- Rob Seitz, Head of Immune Oncology
#CancerResearch #BreastCancer #WhereTomorrowLives $OCX
Continued evidence supports the thesis that DetermaIO™ has utility across multiple cancer types.
https://t.co/sy7DXWi1ph
#bladdercancer #oncology #biomarkers #DetermaIO $OCX
@OncocyteCorp is developing the most comprehensive and rapid tumor- microenvironment gene-expression test to assess immunotherapeutic responsiveness. Determining immunotherapeutic responsiveness one test at a time! #DetermaIO
#wheretomorrowlives $OCX https://t.co/oGLF1Kti7E
#DetermaIO Correctly Predicted Durable Response in 85% of Patients in two Korean NSCLC Cohorts – Nielsen et al. 2021 #oncology #wheretomorrowlives https://t.co/2oLJtKbuVE
new publications
~@PrivoTechnology announces @NatureComms publication
~@OncocyteCorp's publication validates #DetermaIO in predicting #ImmuneTherapy response in #MetastaticBladderCancer
~@nanostringtech’s GeoMx Digital #SpatialProfiler study featured on cover of @NatureGenet
Oncocyte Announces Publication of the Validation of DetermaIO™ in Predicting Immune Therapy Response in Metastatic Bladder Cancer
https://t.co/sy7DXWi1ph
#bladdercancer #oncology #biomarkers #DetermaIO $OCX
The IMvigor210 results demonstrate the potential for the #DetermaIO Score as a clinically useful biomarker in metastatic urothelial cancer (mUC). As this is the third tumor type assessed using the same algorithm and threshold,... https://t.co/61ckPYF029
Independent (RCT) evidence indicated that DetermaIO™ can identify responders and expand the market for immune checkpoint inhibitor (ICI) therapy in colorectal cancer.
https://t.co/RQEriv38we
#cancer #oncology #DetermaIO #colorectalcancer #ImmuneCheckpointInhibitor $OCX
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
113.6M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.5M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.7M followers
KATY PERRY
@katyperry
89.5M followers
Taylor Swift
@taylorswift13
83.4M followers
Lady Gaga
@ladygaga
74.9M followers
Virat Kohli
@imvkohli
72.6M followers
Kim Kardashian
@kimkardashian
70.7M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65.6M followers
Bill Gates
@billgates
64.9M followers
Selena Gomez
@selenagomez
62.6M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers